

# Research

## Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis

Nina Buscemi, Ben Vandermeer, Nicola Hooton, Rena Pandya, Lisa Tjosvold, Lisa Hartling, Sunita Vohra, Terry P Klassen, Glen Baker

### Abstract

**Objective** To conduct a systematic review of the efficacy and safety of exogenous melatonin in managing secondary sleep disorders and sleep disorders accompanying sleep restriction, such as jet lag and shiftwork disorder.

**Data sources** 13 electronic databases and reference lists of relevant reviews and included studies; Associated Professional Sleep Society abstracts (1999 to 2003).

**Study selection** The efficacy review included randomised controlled trials; the safety review included randomised and non-randomised controlled trials.

**Quality assessment** Randomised controlled trials were assessed by using the Jadad Scale and criteria by Schulz et al, and non-randomised controlled trials by the Downs and Black checklist.

**Data extraction and synthesis** One reviewer extracted data and another reviewer verified the data extracted. The inverse variance method was used to weight studies and the random effects model was used to analyse data.

**Main results** Six randomised controlled trials with 97 participants showed no evidence that melatonin had an effect on sleep onset latency in people with secondary sleep disorders (weighted mean difference  $-13.2$  (95% confidence interval  $-27.3$  to  $0.9$ ) min). Nine randomised controlled trials with 427 participants showed no evidence that melatonin had an effect on sleep onset latency in people who had sleep disorders accompanying sleep restriction ( $-1.0$  ( $-2.3$  to  $0.3$ ) min). 17 randomised controlled trials with 651 participants showed no evidence of adverse effects of melatonin with short term use (three months or less).

**Conclusions** There is no evidence that melatonin is effective in treating secondary sleep disorders or sleep disorders accompanying sleep restriction, such as jet lag and shiftwork disorder. There is evidence that melatonin is safe with short term use.

### Introduction

Sleep disorders affect approximately 20% of the American population.<sup>1</sup> A sleep disorder exists whenever a lower quality of sleep leads to impaired functioning or excessive sleepiness.<sup>2</sup> Sleep disorders place a burden on society due to their negative impact on quality of life, safety, productivity, and healthcare utilisation.

One category of sleep disorders is secondary sleep disorders, sleep problems that are associated with medical, neurological, or substance misuse disorders. Another category of sleep disorders arises from sleep restriction: inadequate sleep results from imposed or self imposed lifestyle and work schedules, such as air travel and shift work.<sup>1</sup>

Complementary and alternative medicine has been used increasingly to manage sleep disorders. One of the most popular treatments of this type is melatonin, a hormone that is secreted by the pineal gland and is linked to the circadian rhythm.<sup>3</sup>

We conducted a systematic review of the efficacy and safety of exogenous melatonin in managing secondary sleep disorders and sleep disorders accompanying sleep restriction, such as jet lag and shiftwork disorder. Our findings can help to guide clinicians and patients in treatment decisions regarding the use of exogenous melatonin in the management of these conditions.

### Methods

#### Search strategy

A health sciences librarian conducted a comprehensive search to identify relevant English-language studies. We searched 13 electronic databases (table 1; see [bmj.com](http://bmj.com) for search terms). The reference lists of relevant reviews, as well as a random sample of included studies, were reviewed to identify other potentially relevant studies. We hand searched abstracts of meetings of the Associated Professional Sleep Society from 1999 to 2003. Finally, we searched Medline and Embase again in early 2004 to identify recently published studies.

#### Study selection

The full text of all articles deemed potentially relevant was retrieved and reviewed independently by two reviewers. To assess the efficacy of exogenous melatonin, we included randomised controlled trials that involved human participants who had a secondary sleep disorder or a sleep disorder accompanying sleep restriction; compared melatonin to placebo; and reported on one or more of: sleep onset latency (amount of time between lying down to sleep and onset of sleep), sleep efficiency (amount of time spent asleep as a percentage of total time spent in bed), sleep quality (perceived quality of sleep), wakefulness after sleep onset (amount of time spent awake in bed after first attainment



Search terms used are on [bmj.com](http://bmj.com)

**Table 1** Biomedical databases searched for articles on exogenous melatonin in managing secondary sleep disorders and sleep disorders accompanying sleep restriction

Database	Platform	Dates covered by search
Medline	Ovid	1966 to 30 June 2003
PreMedline	Ovid	1970 to 30 June and 4 July 2003
Embase	Ovid	1988 to 30 June 2003
PubMed	NA	1950 to 9 July 2003
CAB Health	SilverPlatter version 4.3	1973 to 8 July 2003
CINAHL	Ovid	1982 to 30 June 2003
Cochrane Central Register of Controlled Trials	Ovid	3rd quarter 2003; 2 July 2003
Science Citation Index	ISI Web of Knowledge	1945 to 4 July 2003
Biological Abstracts	SilverPlatter version 4.3	1969 to 4 July 2003
International Pharmaceutical Abstracts	Ovid	1970 to 12 August 2003
NLM Gateway	http://gateway.nlm.nih.gov/gw/Cmd	1950 to 13 August 2003
OCLC Papers First and Proceedings First	OCLC FirstSearch	1993 to 11 July 2003
Toxline	CSA Internet Database Service	1965 to 4 July 2003

of sleep), total sleep time (total time spent asleep while in bed), or percentage of time in rapid eye movement (REM) sleep.

To assess the safety of exogenous melatonin, we included randomised and non-randomised trials meeting the first two criteria above and reporting on adverse events. A study population was considered to have a secondary sleep disorder if the participants, as a group, were defined by a specific chronic medical or psychiatric disorder and this disorder was likely to be the cause of the sleep disorder. A study population was considered to have been exposed to sleep restriction if participants had been exposed to transmeridian air travel, shiftwork, or other forms of sleep schedule alteration. Disagreements regarding inclusion of studies were resolved through discussion.

### Quality assessment

Two reviewers assessed study quality independently. For the efficacy review, randomised controlled trials were assessed for methodological quality with the validated Jadad scale.<sup>4</sup> In addition, concealment of treatment allocation was assessed using the criteria of Schulz et al.<sup>5</sup> Allocation concealment was considered to be adequate if group allocation was accomplished by using such methods as central randomisation, numbered or coded containers, drugs prepared by a pharmacy, or serially numbered, opaque, sealed envelopes. For the safety review, which relied on evidence from randomised and non-randomised trials, the Downs and Black checklist was used.<sup>6</sup> Disagreements regarding quality assessment were resolved through discussion.

### Data extraction

Data were extracted by using a standardised data extraction form that captured details of study design, population, intervention, and outcomes. A trained reviewer extracted data and a second reviewer verified the extracted data. Disagreements were resolved through discussion.

### Data analysis

We listed our outcomes in order of importance, with sleep onset latency as most important (primary outcome), followed by sleep efficiency, sleep quality, wakefulness after sleep onset, total sleep time, and percentage of time in REM sleep. Continuous outcomes were combined, using a weighted mean difference, with the exception of sleep quality, for which studies were combined by using a standardised mean difference. Dichotomous outcomes were combined by using a risk difference. The inverse

variance method was used to weight the studies.<sup>7</sup> All meta-analyses used a random effects model. A point estimate with corresponding 95% confidence interval was computed for each outcome, using the generic inverse variance function in RevMan 4.2.5 (Update Software, 2004).

In most cases, we were able to calculate the efficacy estimate for each study exactly, but occasionally estimates had to be made by extracting from graphs or using medians. Standard errors of the differences were calculated from available data (individual patient data or exact P values) whenever possible. For studies with a crossover design, we used the methods of Elbourne et al to compute standard errors of differences,<sup>8</sup> and a correlation of 0.5 was imputed when it could not be calculated from available data.

All pooled estimates were assessed for heterogeneity, using the  $I^2$  statistic.<sup>9</sup> For our primary outcome, we planned to explore heterogeneity in subgroup and sensitivity analyses. We also conducted a post hoc sensitivity analysis. Deeks'  $\chi^2$  statistic<sup>10</sup> was used to test for significant heterogeneity reduction in partitioned subgroups (age, comorbidity, type of sleep disorder, dosage, treatment duration, outcome measurement method, study design, study quality, and allocation concealment).

We tested for publication bias visually using the funnel plot and quantitatively using the rank correlation test,<sup>11</sup> the graphical test,<sup>12</sup> and the trim and fill method.<sup>13</sup> Publication bias graphs and calculations were produced with STATA 7.0 (Stata Corporation, 2001).

## Results

Figure 1 shows the flow of studies through the selection process.

### Secondary sleep disorders

#### Efficacy

Table 2 describes the nine trials (279 participants) included in the efficacy analysis for secondary sleep disorders.<sup>14-25</sup> The median quality score, based on the Jadad scale, was 4 out of 5 (interquartile range 2-4). Concealment of allocation was unclear in all studies except one,<sup>23</sup> which had adequate allocation concealment. Only five studies described a funding source; for all of these studies, funding was received from public sponsors.<sup>18-23</sup>

#### Sleep onset latency

Table 3 outlines the means and standard deviations for sleep onset latency for placebo and melatonin groups for the six trials providing data on this outcome.<sup>15 18 19 21-23</sup> The studies produced a combined estimate that favoured melatonin but was not significant (weighted mean difference -13.2 (95% confidence interval -27.3 to 0.9) min) (fig 2). Heterogeneity among the studies was substantial ( $I^2=79.2\%$ ) due primarily to one study<sup>23</sup> that had a very small standard deviation and an estimate that favoured placebo, whereas the other studies had point estimates that favoured melatonin.

The results for planned subgroup and sensitivity analyses are shown in table 4. In the only two categories for which the confidence intervals across subgroups did not overlap, a study by Shamir et al seemed to be highly influential.<sup>23</sup> Subgroups that omitted this study (actigraphy and questionnaire methods of measuring sleep outcomes and unclear allocation concealment) showed a significant result in favour of melatonin with minimal heterogeneity, while the point estimate for this study showed a significant effect in favour of placebo.

We conducted a post hoc sensitivity analysis excluding the study by Shamir et al from the primary analysis. When the study was included in the analysis, the point estimate was -13.2

**Table 2** Characteristics of trials of melatonin in people with secondary sleep disorders

Study and year	No enrolled (analysed)	Mean (SD or range) age (years)	% male	Disorder	Intervention			Design
					Formulation	Dosage and timing (route)	Frequency and duration	
Camfield et al, 1996 <sup>14*</sup>	6	8.8 (3 to 13)	67	Developmental disability	NS	0.5 or 1.0 mg at 1800 (oral)	For each 2 week interval of 10 week trial, children received melatonin or placebo nightly during first week with alternative agent given on second week	N-of-1 RCT
Dodge and Wilson, 2001 <sup>15</sup>	36 (17)	7.4 (1 to 15)	NS	Developmental disability	NS	5 mg at 2000 (oral)	5 mg/day for weeks 2-3 and 5-6 of 6 week study	RCT; crossover
Jan et al, 1994 <sup>16,†</sup>	15	NS (0.5-14)	87	Neurological impairment	NS	2-5 mg at bedtime (NS)	2-5 mg/day for up to 12 months	N-of-1 RCT
Jean-Louis et al, 1998 <sup>17,†</sup>	10	68.8 (15.8)	40	Mild cognitive impairment	NS	6 mg 2 h before bedtime (NS)	6 mg/day for 10 days	Non-RCT; crossover
McArthur and Budden, 1998 <sup>18</sup>	9	10.1 (1.5)	0	Rett syndrome	Immediate release	2.5-7.5 mg (depending on body weight) given 1 h before bedtime (oral or gastrostomy tube)	1 capsule/day for 4 weeks	RCT; crossover
O'Callaghan et al, 1999 <sup>19</sup>	7	Median=11 (2-28)	43	Tuberous sclerosis	NS	5 mg 20 min before bedtime (oral)	1 capsule/day for 2 weeks	RCT; crossover
Serfaty et al, 2002 <sup>20</sup>	44 (25)	84.2 (7.6)	64	Dementia	Slow release	6 mg tablet at usual bedtime (oral)	1 tablet/day for 2 weeks	RCT; crossover
Serfaty et al, 2003 <sup>21*</sup>	33 (31)	39.9 (11.8)	45	Major depression	Slow release	6 mg tablet at bedtime (oral)	1 tablet/day for 4 weeks	RCT; parallel
Shamir et al, 2000 <sup>22*</sup>	27 (19)	42 (5)	63	Schizophrenia	Controlled release	2 mg 2 h before bedtime (NS)	2 mg/day for 3 weeks	RCT; crossover
Shamir et al, 2000 <sup>23*</sup>	14	42.3 (13.1)	79	Schizophrenia	Controlled release	2 mg 2 h before bedtime (NS)	2 mg/day for 3 weeks	RCT; crossover
Singer et al, 2003 <sup>24*</sup>	157 (151)	77.4 (8.9)	44	Alzheimer's disease	Slow release and immediate release	2.5 mg (SR) or 10 mg (IR) 1 h before bedtime (oral)	1 capsule/day for 8 weeks	RCT; parallel
Van Wieringen et al, 2001 <sup>25,†</sup>	81	33.4 (10.7)	27	Chronic whiplash syndrome	NS	5 mg 5 h before individual dim light melatonin onset time (oral)	1 tablet/day for 4 weeks	RCT; parallel

NS=not specified; RCT=randomised controlled trial.


\*Included in efficacy review only; †included in safety review only.

(−27.3 to 0.9) min; when it was excluded, the point estimate was −17.4 (−26.4 to −8.4) min. Although the point estimate did not change substantially, the confidence interval narrowed, rendering the result significant.

Not enough studies examined sleep onset latency for publication bias to be tested on the basis of this outcome.

#### Other efficacy outcomes

Six trials reporting data for sleep efficiency showed a significant effect that favoured melatonin (weighted mean difference 1.9% (0.5 to 3.3);  $I^2 = 0\%$ )<sup>18, 20-24</sup>; however, the effect seems not to be clinically important. The results for other efficacy outcomes are shown in table 4.

**Fig 1** Retrieval and selection of studies of exogenous melatonin in management of secondary sleep disorders and sleep disorders accompanying sleep restriction

**Table 3** Sleep onset latency (minutes) with melatonin and placebo in people with secondary sleep disorders

Study	Design	Method of computing SE of difference between melatonin and placebo	Melatonin		Placebo		Mean (95% CI) difference
			No in study	Mean (SD)	No in study	Mean (SD)	
Dodge and Wilson, 2001 <sup>15</sup>	Crossover	SDs using estimated correlation of 0.5	17	42 (48)	17	72 (72)	-30.0 (-60.2 to 0.2)
McArthur and Budden, 1998 <sup>18</sup>	Crossover	SDs using estimated correlation of 0.5	9	19.1 (15.9)	9	32.0 (25.8)	-12.9 (-27.6 to 1.8)
O'Callaghan et al, 1999 <sup>19</sup>	Crossover	From exact P value of difference	7	Not provided: only difference values were provided	7	Not provided: only difference values were provided	-23.4 (-45.2 to -1.6)
Serfaty et al, 2003 <sup>21</sup>	Parallel	From SDs of change from baseline scores using a correlation estimate of 0.5	16	Baseline 39.8 (31.2); melatonin 33.3 (31.9)	15	Baseline 21.9 (17.1); Melatonin 28.9 (24.3)	-13.5 (-32.5 to 5.5)
Shamir et al, 2000 <sup>22</sup>	Crossover	SDs using estimated correlation of 0.5	14	12.2 (7.3)	14	6.4 (3.8)	5.8 (2.5 to 9.1)
Shamir et al, 2000 <sup>23</sup>	Crossover	From exact P value of difference	19	26.0 (25.4)	19	46.5 (56.0)	-20.5 (-44.4 to 3.4)

**Safety**  
 Seven studies were included in the safety analysis<sup>15-20 25</sup>; one was non-randomised and six were randomised (table 2). The studies included 164 participants. The quality of these studies was good (median quality index 21 (out of 29); range 20-22). The most commonly reported adverse events were headaches, dizziness, nausea, and drowsiness. The occurrence of these outcomes was similar for melatonin and placebo (table 4).

**Sleep restriction**

**Efficacy**  
 Table 5 describes the nine trials included in the efficacy analysis for sleep restriction.<sup>26 29-32 35-38</sup> The trials encompassed 427 participants. The median quality score was 4 out of 5 (interquartile range 3-4). Concealment of allocation was unclear in all studies except three,<sup>29 32 38</sup> which had adequate allocation concealment. None of the studies described a funding source.

**Sleep onset latency**  
 Table 6 outlines the mean and standard deviations for sleep onset latency for placebo and melatonin groups for the nine trials that provided data on this outcome.<sup>26 29 32 35-37</sup> The studies produced a combined estimate that favoured melatonin but was not significant (weighted mean difference -1.0 (-2.3 to 0.3) min; I<sup>2</sup> = 4.0%) (fig 3).

The results for planned subgroup and sensitivity analyses are in table 7. The subgroups did not differ significantly in any of the categories (all confidence intervals were overlapping, and in all but two cases (<1 mg dose and parallel study design), results were non-significant).

Given that the study by Folkard et al<sup>29</sup> was allotted a high proportion of weight in the primary analysis but had a small sample size, we conducted a post hoc sensitivity analysis excluding this study. When the Folkard study was excluded from the analysis, there was almost no change in the point estimate and the confidence interval widened slightly: (-1.03 (-3.59 to 1.53) min when excluded v -0.97 (-2.26 to 0.33) min).


The funnel plot for sleep onset latency showed no obvious signs of asymmetry. There were also no indications of publication bias with Begg's test (P=0.35; n=9); Egger's test (P=0.48); and Duval's trim and fill method (no new studies added).

**Other efficacy outcomes**

For sleep efficiency, the combined estimate from five trials<sup>26 30-32 37</sup> showed no significant difference between melatonin and placebo (weighted mean difference 0.5% (-0.6 to 1.6); I<sup>2</sup> = 20.9%). The results for other efficacy outcomes are in table 7.

**Safety**

Of the 10 studies included in the safety analysis,<sup>27 28 30-36 38</sup> all studies but one<sup>28</sup> were randomised controlled trials (table 5). The studies included 487 participants. The methodological quality of these studies was good (median quality index 21 (out of 29); range 20-22). The most commonly reported adverse events were headache, dizziness, nausea, and drowsiness. The occurrence of these outcomes did not differ significantly for melatonin versus placebo (table 7).



**Fig 2** Sleep onset latency in people with secondary sleep disorders

**Table 4** Efficacy and safety outcomes and subgroup and sensitivity analyses for trials of melatonin in people with secondary sleep disorders

Outcome	No of studies	Melatonin group	Placebo group	Summary measure	Point estimate (95% CI)
<b>Efficacy</b>					
Sleep onset latency (min)	6	82	81	WMD	-13.2 (-27.3 to 0.9)
Sleep efficiency (%)	6	187	129	WMD	1.9 (0.5 to 3.3)
Wakefulness after sleep onset (min)	3	137	80	WMD	-6.3 (-16.6 to 3.9)
Total sleep time (min)	9	220	162	WMD	15.6 (7.2 to 24.0)
REM sleep (%)	1	14	14	WMD	-1.5 (-4.4 to 1.4)
<b>Adverse events</b>					
Headaches	7	127	126	RD	0.02 (-0.03 to 0.07)
Dizziness	7	127	126	RD	0 (-0.03 to 0.03)
Nausea	7	127	126	RD	0 (-0.03 to 0.03)
Drowsiness	7	127	126	RD	0 (-0.03 to 0.03)
<b>Subgroup and sensitivity analyses of sleep onset latency</b>					
Age (years)*:					
Children (0-18)	3	33	33	WMD	-18.1 (-29.4 to -6.8)
Adults (19-65)	3	49	48	WMD	-6.6 (-24.6 to 11.4)
Co-morbidity*:					
Rett syndrome	1	9	9	WMD	-12.9 (-27.6 to 1.8)
Tuberous sclerosis	1	7	7	WMD	-23.4 (-45.2 to -1.6)
Developmental disabilities	1	17	17	WMD	-30.0 (-60.2 to 0.2)
Depression	1	16	15	WMD	-13.5 (-32.5 to 5.5)
Schizophrenia	2	33	33	WMD	-4.6 (-29.8 to 20.6)
Dosage (mg):					
1-3	2	33	33	WMD	-4.6 (-29.8 to 20.6)
4-5	1	7	7	WMD	-23.4 (-45.2 to -1.6)
6-10	1	16	15	WMD	-13.5 (-32.5 to 5.5)
Duration (weeks)*:					
1-2	2	24	24	WMD	-25.7 (-43.3 to -8.0)
3-4	2	33	33	WMD	-4.6 (-29.8 to 20.6)
>4	2	25	24	WMD	-13.1 (-24.8 to -1.5)
Measurement method*:					
Polysomnography	1	14	14	WMD	5.8 (2.5 to 9.1)
Actigraphy	3	44	43	WMD	-14.5 (-25.0 to -4.1)
Questionnaire	2	24	24	WMD	-25.7 (-43.3 to -8.0)
Study design:					
Parallel	1	16	15	WMD	-13.5 (-32.5 to 5.5)
Crossover	5	66	66	WMD	-13.5 (-29.7 to 2.8)
Allocation concealment*:					
Unclear	5	68	67	WMD	-17.4 (-26.4 to -8.4)
Adequate	1	14	14	WMD	5.8 (2.5 to 9.1)

WMD = weighted mean difference; RD= risk difference

\*P<0.001, Deeks  $\chi^2$  test.

## Discussion

This review of the effects of exogenous melatonin on people with secondary sleep disorders or sleep disorders accompanying sleep restriction showed that melatonin does not have a significant effect on sleep onset latency in either disorder or on sleep efficiency in people with sleep disorders accompanying sleep restriction. Although the increase in sleep efficiency in people with secondary sleep disorders was statistically significant with melatonin, the effect was small—1.9%—an increase of less than 10 minutes in the amount of time spent asleep for eight hours spent in bed. On the basis of advice from clinical sleep experts, we considered this effect to be clinically unimportant, due to its small magnitude.

### Factors affecting heterogeneity

The effect of melatonin on sleep onset latency in studies of people with secondary sleep disorders was associated with substantial heterogeneity, which seemed to be highly influenced by the study by Shamir et al.<sup>23</sup> This study was unique in that polysomnography was used to assess sleep outcomes and the method of concealing treatment allocation was reported and

adequate. Although the estimation of sleep variables differs according to the assessment tool used to measure them,<sup>39</sup> the heterogeneity in results across studies is unlikely to be due to variation in assessment tool, as any differences between methods would have been cancelled out when absolute differences in the effect of treatment and placebo were obtained.

Regarding the effect of allocation concealment on effect estimates, failure to conceal treatment allocation adequately is associated with larger effect estimates.<sup>5–40</sup> Allocation concealment may have been inadequate in the studies for which the adequacy of allocation concealment was unclear, which would tend to result in overestimation of treatment effect. Also, the heterogeneity across studies may have been due to publication or reporting bias, such that small studies with negative results were not published and therefore under-represented in the analysis; as this category included only nine studies, we could not verify this bias.

Other factors may have contributed to heterogeneity in results across studies of secondary sleep disorders. Formulations of melatonin vary in quality. In studies that reported details of the intervention, the rate of release of melatonin varied from slow to

**Table 5** Characteristics of trials of people with sleep disorders accompanying sleep restriction

Study and year	No enrolled (analysed)	Mean (SD or range) age (years)	% male	Disorder	Intervention			Design
					Formulation	Dosage and timing (route)	Frequency and duration	
Beaumont et al, 2004 <sup>26*</sup>	27 (18)	35.3 (8.1)	67	Jet lag	NS	5 mg on day -1 at 1700; on day 0 at 1600; on day 1 to day 3 at 2300 (NS)	5 mg/day for 5 days	RCT; parallel
Claustrat et al, 1992 <sup>27†</sup>	37 (15)	Melatonin 36.3 (8.9); placebo: 35.7 (6.4)	Melatonin 53; placebo 67	Jet lag	NS	8 mg at 2200 (oral)	1 capsule/day for 4 days	RCT; parallel
Edwards et al, 2000 <sup>28†</sup>	31	Melatonin 40 (13); placebo 41 (12)	Melatonin 93; placebo 88	Jet lag	NS	5 mg taken on plane between 1800 to 1900 and between 2200 to 2300, according to local time at destination and for next 3 evenings	2 capsules/day for first day and then 1 capsule/day for 3 days	non-RCT; parallel
Folkard et al, 1993 <sup>29*</sup>	17 (7)	29 (7)	88	Shiftwork disorder	NS	5 mg at 0642 ±7.6 min (oral)	1 capsule/day for 6 successive day sleeps taken between night shifts	RCT; crossover
James et al, 1998 <sup>30</sup>	24 (22)	29 (8)	77	Shiftwork disorder	NS	6 mg 0.5 h before each consecutive day sleep (oral)	6 mg/day for 4 treatment cycles lasting 4 to 6 consecutive night shifts	RCT; crossover
Jockovich et al, 2000 <sup>31</sup>	19	28.2 (NS)	21	Shiftwork disorder	NS	1 mg 0.5 to 1 h before daytime sleep (oral)	1 caplet/day for 3 consecutive days	RCT; crossover
Jorgensen and Witting, 1998 <sup>32</sup>	20 (18)	32 (25 to 40)	89	Shiftwork disorder	NS	10 mg morning after each night shift (oral)	1 tablet/day for varied amount of time	RCT; crossover
Petrie et al, 1989 <sup>33†</sup>	20 (15)	NS (28 to 68)	60	Jet lag	NS	5 mg taken between 1000 and 1200 local time; also taken at the same time during the flight and between 2200 and 2400 (destination time) after arrival (NS)	1 dose for 3 days before flight, 1 dose during flight, and 1 dose/day for 3 days after arrival	RCT; crossover
Petrie et al, 1993 <sup>34†</sup>	52 (44)	34.9 (7.7)	50	Jet lag	NS	5 mg taken between 0700 to 0800	5 mg early melatonin for 8 days, 5 mg late melatonin for 5 days	RCT; parallel
Suhner et al, 1998 <sup>35</sup>	320 (234)	20 to 65	54	Jet lag	Fast release and controlled release	0.5 mg fast release, 5 mg fast release, or 2 mg controlled release melatonin on first day after flight at 2310 and on subsequent days at 2329 (NS)	1 dose/day for 4 days after eastward flight	RCT; parallel
Suhner et al, 2001 <sup>36</sup>	160 (74)	41.3 (18 to 68)	51	Jet lag	NS	5 mg taken on return flight (eastbound) between 1700 and 2100 local time at the place of departure depending on flight schedule (NS)	1 dose/day on return flight and for 4 consecutive days after flight	RCT; parallel
Waldhauser et al, 1990 <sup>37*</sup>	20 (20)	26.4 (4.8)	50	Induced insomnia	NS	80 mg at 2100 (oral)	Single dose	RCT; parallel
Wright et al, 1998 <sup>38</sup>	20 (15)	38.6 (32 to 45)	80	Shiftwork disorder	NS	5 mg 30 min before bedtime in the evening (oral)	5 mg/night for 3 nights following shift work	RCT; crossover

NS=not specified.

\*Included in efficacy review only; †included in safety review only.

fast, a range of doses was used, and the duration of administration varied from days to weeks. Indeed, our results show that dosage and duration of melatonin administration explain a considerable amount of heterogeneity across studies.

Two other systematic reviews examining the use of melatonin for jet lag concluded that melatonin is effective in alleviating the symptoms of jet lag.<sup>41 42</sup> These reviews examined the effect of melatonin on both the daytime fatigue and the sleep disturbance aspects of jet lag. Our review shows that melatonin does not affect either sleep onset latency or sleep efficiency in people with jet lag or people with shiftwork disorder. Our results do not provide evidence that melatonin is effective in alleviating sleep disturbance in jet lag, but we did not determine the effect of melatonin on measures of daytime fatigue.

**Other limitations**

The observations of this review are based mostly on studies with relatively short durations, so the efficacy and safety of melatonin reported here may reflect only its short term effects. Secondly,

several studies did not report adequately on details of the intervention, such as content, quality, and formulation of the melatonin product under study, nor on methods of allocation concealment or source of funding, which casts doubt on the methodological quality of these studies, despite a good median Jadad score or Downs and Black quality index. Thirdly, non-English language reports were excluded from the review; however, we did not find strong evidence of publication bias, so it is unlikely that the inclusion of these reports would have altered our findings substantially.

We thank the National Centre for Complementary and Alternative Medicine, National Institutes of Health for sponsoring this research, through the Agency for Healthcare Research and Quality. We are grateful to members of our technical expert panel for providing input on the direction and scope of the review. We are especially grateful to Manisha Witmans for her input on the manuscript.

Contributors: NB planned, oversaw, and participated in all steps of the systematic review process and in writing and editing the manuscript. BV performed all statistical analyses and participated in writing and editing the

**Table 6** Sleep onset latency (minutes) in people with sleep disorders accompanying sleep restriction

Study	Design	Method of computing SE of difference between melatonin and placebo	Melatonin		Placebo		Mean (95% CI) difference
			No	Mean (SD)	No	Mean (SD)	
Beaumont et al, 2004 <sup>26</sup>	Parallel	From SDs	9	29.7 (14.0)	9	32.2 (14.3)	-2.6 (-15.7 to 10.5)
Folkard et al, 1993 <sup>29</sup>	Crossover	SDs using estimated correlation of 0.5	7	4.5 (1.6)	7	5.6 (1.8)	-1.1 (-2.3 to 0.2)
James et al, 1998 <sup>30</sup>	Crossover	From exact P value of difference	22	15 (7.0)	22	16 (9.0)	-1.0 (-5.7 to 3.7)
Jockovich et al, 2000 <sup>31</sup>	Crossover	From exact P value of difference	19	7.6 (not provided)	19	6.8 (not provided)	0.8 (-2.7 to 4.3)
Jorgensen and Witting, 1998 <sup>32</sup>	Crossover	From confidence interval of difference	18	13.6 (not provided)	18	15.6 (not provided)	-2.0 (-7.5 to 3.5)
Suhner et al, 1998 <sup>35</sup>	Parallel	Estimated from upper bound of P value	174	19.4 (not provided)	60	32.1 (not provided)	-12.6 (-25.2 to -0.1)
Suhner et al, 2001 <sup>36</sup>	Parallel	From SDs	35	21.7 (23.7)	39	21.2 (27.3)	0.5 (-11.1 to 12.1)
Waldhauser et al, 1990 <sup>37</sup>	Parallel	Estimated from upper bound of P value	10	14.7 (not provided)	10	23.7 (not provided)	-9.0 (-19.2 to 1.2)
Wright et al, 1998 <sup>38</sup>	Crossover	SDs using estimated correlation of 0.5.	15	22.3 (14.2)	15	19.0 (13.7)	3.3 (-3.8 to 10.4)

manuscript. NH participated in most steps of the systematic review process and in writing and editing the manuscript. RP participated in all steps of the systematic review process and reviewed the manuscript. LT conducted the literature search, provided technological expertise for the inclusion process, and participated in editing the manuscript. LH participated in writing the proposal, provided methodological expertise, and participated in writing and editing the manuscript. SV participated in writing the proposal, provided methodological and content expertise, and participated in editing the manuscript. TK participated in writing the proposal, provided methodological expertise, and provided feedback on the manuscript. GB participated in writing the proposal, provided content expertise, and participated in writing and editing the manuscript. Michelle Tubman, Mia Lang, Maria Ospina, Victor Juorio, and Ellen Crumley were involved in study selection, quality assessment, and data extraction or entry. TK is guarantor.


**Funding:** This study was conducted under contract to the Agency for Healthcare Research and Quality (contract No 290-02-0023), Rockville, MD, and support from the National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD. SV is supported by Agency for Healthcare Research and Quality (AHRQ), USA; Canadian Institutes of Health Research; Change Foundation; Department of Pediatrics; National Health Products Directorate, Health Canada; Ontario Mental Health Foundation; Stollery Children's Hospital and Foundation; The Hospital for Sick Children Foundation; and the University of Alberta. GB is supported by AHRQ; Canadian Institutes of Health Research; Canada Research Chairs Program; Stanley Foundation; University of Alberta Hospital Foundation; Bebensee Schizophrenia Research Fund; Davey Endowment; and Zyprexa Research Foundation. The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should

be construed as an official position of the Agency for Healthcare Research and Quality, the National Center for Complementary and Alternative Medicine or the US Department of Health and Human Services.

Competing interests: None declared.

Ethical approval: Not required.

- 1 National Institutes of Health. National Center on Sleep Disorders Research Plan. 2003. [www.nhlbi.nih.gov/health/prof/sleep/res\\_plan/sleep-rplan.pdf](http://www.nhlbi.nih.gov/health/prof/sleep/res_plan/sleep-rplan.pdf) (accessed 14 Jan 2006).
- 2 Roller L. Treating sleep disorders. *Austral J Pharm* 2002;83:443-7.
- 3 Reiter RJ. Melatonin: clinical relevance. *Best Pract Res Clin Endocrinol Metab* 2003;17:273-85.
- 4 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Controlled Clin Trials* 1996;17:1-12.
- 5 Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;273:408-12.
- 6 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions. *J Epidemiol Commun Health* 1998;52:377-84.
- 7 Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. *Methods for meta-analysis in medical research*. Chichester: Wiley, 2000:58.
- 8 Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials. *Int J Epidemiol* 2002;31:140-9.
- 9 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539-58.
- 10 Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Eggar M, Smith GD, Altman DG, eds. *Systematic reviews in health care: meta-analysis in context*. 3rd ed. London: BMJ Publishing Group, 2001:285-312.
- 11 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088-101.



**Fig 3** Sleep onset latency in people with sleep disorders accompanying sleep restriction

**Table 7** Efficacy and safety outcomes and subgroup and sensitivity analyses for trials of people with sleep disorders accompanying sleep restriction

Outcome	No of studies	No in melatonin group	No in placebo group	Summary measure	Point estimate (95% CI)
<b>Efficacy</b>					
Sleep onset latency (min)	9	309	199	WMD	-1.0 (-2.3 to 0.3)
Sleep efficiency (%)	5	78	78	WMD	0.5 (-0.6 to 1.6)
Sleep quality (SD)	5	248	138	SMD	0.2 (-0.2 to 0.6)
Wakefulness after sleep onset (min)	2	44	48	WMD	-10.4 (-21.0 to 0.2)
Total sleep time (min)	7	100	100	WMD	18.2 (8.1 to 28.3)
% REM sleep	1	10	10	WMD	-3.6 (-7.3 to 0.1)
<b>Adverse events</b>					
Headaches	9	342	218	RD	-0.01 (-0.05 to 0.02)
Dizziness	9	342	218	RD	0.00 (-0.03 to 0.03)
Nausea	10	356	235	RD	0.00 (-0.03 to 0.02)
Drowsiness	10	356	235	RD	0.00 (-0.03 to 0.03)
<b>Subgroup and sensitivity analyses of sleep onset latency</b>					
Dosage*:					
<1 mg	1	58	60	WMD	-11.8 (-23.6 to -0.0)
1-3 mg	2	77	79	WMD	-4.5 (-17.3 to 8.3)
4-5 mg	5	124	130	WMD	-1.0 (-4.0 to 2.1)
10-20 mg	1	18	18	WMD	-2.0 (-7.5 to 3.5)
Type of sleep disorder:					
Jet lag	3	218	108	WMD	-4.7 (-12.6 to 3.1)
Shiftwork	5	81	81	WMD	-0.8 (-1.9 to 0.3)
Deprivation	1	10	10	WMD	-9.0 (-19.2 to 1.2)
Study design:					
Parallel	4	228	118	WMD	-6.1 (-11.9 to -0.2)
Crossover	5	81	81	WMD	-0.8 (-1.9 to 0.3)
Quality:					
High (Jadad score 4-5)	5	264	154	WMD	-1.2 (-4.6 to 2.3)
Moderate (Jadad score 2-3)	4	45	45	WMD	-0.9 (-2.7 to 0.8)
Allocation concealment:					
Unclear	6	254	144	WMD	-1.4 (-3.8 to 1.1)
Adequate	3	55	55	WMD	-0.5 (-3.7 to 2.7)

WMD = weighted mean difference; SMD = standardised mean difference; RD= risk difference.  
 \*No studies with 6-9 mg dose range.

- 12 Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a single graphical test. *BMJ* 1997;315:629-34.
- 13 Duval S, Tweedie R. A nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. *JAMA* 2000;95:89-98.
- 14 Camfield P, Gordon K, Dooley J, Camfield C. Melatonin appears ineffective in children with intellectual deficits and fragmented sleep: six "N of 1" trials. *J Child Neurol* 1996;11:341-3.
- 15 Dodge NN, Wilson GA. Melatonin for treatment of sleep disorders in children with developmental disabilities. *J Child Neurol* 2001;16:581-4.
- 16 Jan J, Espezel H, Appleton R. The treatment of sleep disorders with melatonin. *Develop Med Child Neurol* 1994;36:97-107.
- 17 Jean-Louis G, von Gizycki H, Zizi F. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. *J Pineal Res* 1998;25:177-83.
- 18 McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. *Developmental Med Child Neurol* 1998;40:186-92.
- 19 O'Callaghan FJK, Clarke AA, Hancock E, Hunt A, Osborne JP. Use of melatonin to treat sleep disorders in tuberous sclerosis. *Developmental Med Child Neurol* 1999;41:123-6.
- 20 Serfaty M, Kennell-Webb S, Warner J, Blizard R, Raven, P. Double blind randomised placebo-controlled trial of low dose melatonin for sleep disorders in dementia. *Int J Geriatr Psychiatry* 2002;17:1120-7.
- 21 Serfaty MA, Osborne D, Buszewicz MJ, Raven PW. The effects of exogenous melatonin in major depression. *Biol Med Rhythm Res* 2003;1191-3.
- 22 Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. *J Clin Psychiatry* 2000;61:373-7.
- 23 Shamir E, Rotenberg VS, Laudon M, Zisapel N, Elizur A. First-night effect of melatonin treatment in patients with chronic schizophrenia. *J Clin Psychopharmacol* 2000;20:691-4.
- 24 Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. *Sleep* 2003;26:893-901.
- 25 Van Wieringen S, Jansen T, Smits MG, Nagtegaal JE, Coenen AML. Melatonin for chronic whiplash syndrome with delayed melatonin onset. *Clin Drug Invest* 2001;21:813-20.
- 26 Beaumont M, Batejat D, Pierard C, Van Beers P, Denis JB, Coste O, et al. Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. *J Appl Physiol* 2004;96:50-8.
- 27 Claustrat B, Brun J, David M, Sassolas G, Chazot G. Melatonin and jet lag: confirmatory result using a simplified protocol. *Biol Psychiatry* 1992;32:705-11.
- 28 Edwards BJ, Atkinson G, Waterhouse J, Reilly T, Godfrey R, Budgett R. Use of melatonin in recovery from jet-lag following an eastward flight across 10 time-zones. *Ergonomics* 2000;43:1501-3.
- 29 Folkard S, Arendt J, Clark M. Can melatonin improve shift workers' tolerance of the night shift? Some preliminary findings. *Chronobiol* 1993;10:315-20.
- 30 James M, Tremea MO, Jones JS, Krohmer JR. Can melatonin improve adaptation to night shift? *Am J Emerg Med* 1998;16:1-7.
- 31 Jockovich M, Cosentino D, Cosentino L, Wears RL, Seaberg DC. Effect of exogenous melatonin on mood and sleep efficiency in emergency medicine residents working night shifts. *Academic Emergency Med* 2000;7:955-8.
- 32 Jorgensen KM, Witting MD. Does exogenous melatonin improve day sleep or night alertness in emergency physicians working night shifts? *Ann Emergency Med* 1998;31:699-704.
- 33 Petrie K, Conaglen JV, Thompson L, Chamberlain K. Effect of melatonin on jet lag after long haul flights. *BMJ* 1989;298:705-7.

**What is already known on this topic**

Sleep disorders are a widespread problem and place a burden on society through their negative impact on quality of life, safety, productivity, and healthcare utilisation

Complementary and alternative therapies, such as melatonin, have been used increasingly to manage sleep disorders

**What this study adds**

There is no evidence that melatonin is effective in treating secondary sleep disorders or sleep disorders accompanying sleep restriction, such as jet lag or shiftwork disorder

There is evidence that melatonin is safe with short term use, but additional studies are needed to determine its long term safety

- 34 Petrie K, Dawson AG, Thompson L, Brook R. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. *Biol Psychiatry* 1993;33:526-30.
- 35 Suhner A, Schlagenhaut P, Johnson R, Tschopp A, Steffen R. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. *Chronobiol* 1998;15:655-6.
- 36 Suhner A, Schlagenhaut P, Hofer I, Johnson R, Tschopp A, Steffen R. Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. *Aviation Space Environmental Med* 2001;72:638-46.
- 37 Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. *Psychopharmacol* 1990;100:222-6.
- 38 Wright SW, Lawrence LM, Wrenn KD, Haynes ML, Welch LW, Schlack HM. Randomized clinical trial of melatonin after night-shift work: efficacy and neuropsychologic effects. *Ann Emergency Med* 1998;32:334-40.
- 39 Vallieres A, Morin CM. Actigraphy in the assessment of insomnia. *Sleep* 2003;26:902-6.
- 40 Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. *N Engl J Med* 1983;309:1358-61.
- 41 Herxheimer A, Petrie KJ. Melatonin for preventing and treating jet lag. *Cochrane Database Syst Rev* 2002;2:CD001520.
- 42 Chase JE, Gidal BE. Melatonin: therapeutic use in sleep disorders. *Ann Pharmacother* 1997;31:1218-26.

(Accepted 18 November 2005)

doi 10.1136/bmj.38731.532766.F6

University of Alberta/Capital Health Evidence-based Practice Centre, Department of Pediatrics, University of Alberta, Edmonton, AB, Canada T6G 2J3

Nina Buscemi *research associate*

Ben Vandermeer *statistician*

Nicola Hooton *project coordinator*

Rena Pandya *project manager*

Lisa Tjosvold *research librarian*

Lisa Hartling *administrative director*

Terry P Klassen *director*

Complementary and Alternative Research and Education Program, Department of Pediatrics, University of Alberta

Sunita Vohra *director*

Department of Psychiatry, University of Alberta

Glen Baker *professor and chair*

Correspondence to: N Buscemi nina.buscemi@ualberta.ca